INVESTMENT: THE FRENCH SGAM FOUNDATION AWARDS FUNDS TO EARLY STAGE FROM SCRATCH
Stepping in relatively early, so as not to miss any business, but not too early, thus reducing the risk and the time of return on investment, that is the art of ideal timing for investment in biotech, and it's far from easy. And while the general trend in Europe is to invest at the latest stage possible, the Société Générale Asset Management (SGAM) is breaking this habit by supporting programs from scratch through its Foundation for Therapeutic Innovation...
More...







